Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cisplatin + paclitaxel + bevacizumab is a combination chemotherapy regimen used primarily for the treatment of advanced, persistent, recurrent, or metastatic cervical cancer. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Paclitaxel is a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis required for tumor growth and metastasis. The addition of bevacizumab to cisplatin-paclitaxel has been shown to improve progression-free survival and overall survival in patients with advanced cervical cancer compared to chemotherapy alone[1][3][5]. This combination may also be used off-label or in clinical trials for other gynecologic malignancies.
- Brand names
- TaxolAvastinMvasi
- Other names
- none
02
Targets
Beyond the preview
Go deeper on cisplatin + paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + paclitaxel + bevacizumab.